期刊
CLINICAL NUCLEAR MEDICINE
卷 48, 期 12, 页码 1049-1050出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/RLU.0000000000004879
关键词
metastatic castration-resistant prostate cancer; PSMA PET/CT; PSMA radioligand therapy; ultrasound-guided fine-needle aspiration cytology; BRCA mutation; next-generation sequencing
For patients with metastatic castration-resistant prostate cancer, PSMA PET/CT can provide valuable information for subsequent treatment. Fine-needle aspiration cytology can be used to evaluate BRCA mutations and guide the selection of appropriate therapeutic options.
A 64-year-old man with metastatic castration-resistant prostate cancer presented for prostate-specific membrane antigen (PSMA) PET/CT in preparation for Lu-177-PSMA radioligand therapy. For precedent BRCA mutation assessment, fine-needle aspiration cytology of 2 PSMA-positive lymph node metastases was conducted. The acquired material was suitable for next-generation sequencing-based gene panel diagnostics and did not show a BRCA1/2 mutation, thus PSMA radioligand therapy was initiated. Fine-needle aspiration cytology of lymph node metastases may be a viable option in evaluating further therapeutic alternatives.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据